BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The BioCalendar - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:The BioCalendar
X-ORIGINAL-URL:https://thebiocalendar.com
X-WR-CALDESC:Events for The BioCalendar
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20270314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20271107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260331T110000
DTEND;TZID=America/Los_Angeles:20260331T120000
DTSTAMP:20260414T201219
CREATED:20260220T125345Z
LAST-MODIFIED:20260220T125345Z
UID:9947-1774954800-1774958400@thebiocalendar.com
SUMMARY:Digital Design Meets Proven Performance: The Future of Single-Use Assemblies
DESCRIPTION:In today’s fast-paced biopharma and CDMO environments\, single-use assembly design is about confidence in quality\, supply continuity\, and process performance. This webinar explores how Thermo Scientific™ Single-Use Assemblies are designed to help reduce risk\, support flexible manufacturing\, and help organizations meet production milestones and maintain momentum when time to market is crucial. \nAttendees will see how automation-driven tools – including the Kaon™ app and the online Single-Use Assembly Configurator\, simplify and standardize assembly design. By bringing a broad\, trusted portfolio of components into one intuitive digital experience\, these tools accelerate design decisions\, improve consistency\, and reduce the effort required to move from concept to execution. \nWe will highlight three core considerations that set Thermo Scientific Single-Use Assemblies apart and deliver tangible value in real-world bioprocessing operations: \n    ~ Film technology for durable\, consistent performance across 2D and 3D bioprocess containers\n    ~ Integration of LifeASSURE™ sterilizing grade filters that streamline qualification\n    ~ Protection of process integrity at critical connection points to reduce risks of leaks \nJoin this webinar to learn how a standardized\, automated configuration experience\, backed by proven Thermo Scientific technologies to help biopharma and CDMO teams move faster\, reduce risk\, and execute with confidence.
URL:https://thebiocalendar.com/event/digital-design-meets-proven-performance-the-future-of-single-use-assemblies/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/02/03-31-26-Thermo-LinkedIn-1280x720-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260331T110000
DTEND;TZID=America/Los_Angeles:20260331T120000
DTSTAMP:20260414T201219
CREATED:20260303T140956Z
LAST-MODIFIED:20260303T140956Z
UID:9983-1774954800-1774958400@thebiocalendar.com
SUMMARY:The Phase 2 Endpoint Dilemma: Bridging Subjective Scales and Objective Measures in Neurodegenerative Trials
DESCRIPTION:Phase 2 neurodegenerative trials are increasingly challenged by slow disease trajectories\, heterogeneous patient populations\, and blunt legacy endpoints that struggle to detect treatment-related change over typical study durations. Traditional scales such as ADAS-Cog and MDS-UPDRS\, while well-established\, often lack sensitivity in early disease\, are vulnerable to rater and practice effects\, and may insufficiently capture subtle but clinically meaningful benefits. \nThis webinar will examine when and how to move beyond single-scale approaches toward more informative composite strategies\, highlighting circumstances in which composites enhance signal detection versus when they introduce additional noise\, complexity\, and interpretability risk. We will explore practical frameworks for integrating functional\, cognitive\, and biomarker measures into coherent endpoint hierarchies that support both mechanistic insight and regulatory relevance. Finally\, we will discuss how real-world evidence and natural history data can be leveraged to select\, calibrate\, and power Phase 2 endpoints capable of detecting meaningful change within shorter trial timeframes\, improving go/no-go decision quality for emerging neurodegenerative therapies. \nKey Learning Objectives:\n– Evaluate the strengths and limitations of traditional subjective scales (e.g.\, ADAS-Cog\, MDS-UPDRS) in Phase 2 neurodegenerative trials and identify when alternative or composite strategies are warranted \n– Apply practical frameworks to integrate cognitive\, functional\, and biomarker endpoints into coherent\, regulator-ready hierarchies that enhance signal detection while minimizing interpretability risk \n– Leverage real-world evidence and natural history datasets to inform endpoint selection\, calibration\, and powering strategies that improve Phase 2 go/no-go decision-making
URL:https://thebiocalendar.com/event/the-phase-2-endpoint-dilemma-bridging-subjective-scales-and-objective-measures-in-neurodegenerative-trials/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/Untitled-design-59.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260407T100000
DTEND;TZID=America/Los_Angeles:20260409T120000
DTSTAMP:20260414T201219
CREATED:20260224T154635Z
LAST-MODIFIED:20260224T154635Z
UID:9968-1775556000-1775736000@thebiocalendar.com
SUMMARY:Cell & Gene Tech Expo
DESCRIPTION:The Cell & Gene Tech Expo is designed to aid professionals in discovering the latest advancements and equipment critical to cell and gene therapy development. Attendees will explore state-of-the-art solutions such as bioreactor systems\, cell sorting and isolation technologies\, automated platforms\, non-viral gene editing tools like electroporation and CRISPR\, data monitoring tools\, sterilization solutions\, and more. \nThis digital event is free for Cell & Gene subscribers and offers an alternative to in-person events which can be costly\, ineffective\, and time-consuming. Through this virtual platform\, professionals can effortlessly connect with various suppliers\, making the selection process more accessible and informed. \nCell Therapy Solutions – April 7\, 2026\nGene Therapy Solutions – April 8\, 2026\nCommercial Readiness – April 9\, 2026
URL:https://thebiocalendar.com/event/cell-gene-tech-expo/
ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2026/02/cellgeneexpo.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260407T163000
DTEND;TZID=America/New_York:20260407T200000
DTSTAMP:20260414T201219
CREATED:20260325T192643Z
LAST-MODIFIED:20260327T171116Z
UID:10069-1775579400-1775592000@thebiocalendar.com
SUMMARY:Builds Bio+ NY Metro Life Science Outlook & Networking Reception
DESCRIPTION:The life sciences and biotech community navigated a historically challenging landscape in 2025. Between shifts in federal agency structures and financial hurdles on Wall Street\, the industry faced significant uncertainty. \nHowever\, innovation has not slowed down. From CRISPR gene-editing breakthroughs to AI-bolstered drug discovery and advances in materials science\, the potential for progress remains stronger than ever. \nJoin Builds Bio+ at Arnold & Porter as we analyze the initiatives driving the region forward. We will discuss the findings of Governor Hochul’s Emerging Technology Advisory Board and explore how 2026 is positioned to propel the NY Metro area to the forefront of global biotechnology. \nLocation: Arnold & Porter\,\n250 West 55th Street\,\nNew York\, NY 10019-9710
URL:https://thebiocalendar.com/event/ny-metro-life-science-outlook-networking-reception/
LOCATION:Arnold & Porter\, 250 West 55th Street\, New York\, 10019\, United States
CATEGORIES:Networking
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/480-x-270-px-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260409
DTEND;VALUE=DATE:20260410
DTSTAMP:20260414T201219
CREATED:20260214T231312Z
LAST-MODIFIED:20260214T231312Z
UID:9906-1775692800-1775779199@thebiocalendar.com
SUMMARY:Life Sciences Future SW
DESCRIPTION:The Life Sciences Future SW conference will unite stakeholders from the region and beyond\, including life sciences start-ups\, established industry leaders\, academic institutions\, healthcare providers\, and investors. \nThis event will strengthen connections with the Southwest region while fostering new relationships across the state. The conference aims to create a more cohesive and thriving regional ecosystem that supports business growth\, innovation\, and collaboration in the life sciences sector.
URL:https://thebiocalendar.com/event/life-sciences-future-sw-2/
LOCATION:Pittsburgh\, Pittsburgh\, PA\, United States
CATEGORIES:Summit
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260409T110000
DTEND;TZID=America/Los_Angeles:20260409T120000
DTSTAMP:20260414T201219
CREATED:20260308T190217Z
LAST-MODIFIED:20260308T190217Z
UID:9992-1775732400-1775736000@thebiocalendar.com
SUMMARY:Defined Media\, Defined Results: Scaling E. coli from Bench to Fermenter
DESCRIPTION:Microbial systems are foundational to plasmid DNA and recombinant protein production\, yet scaling from development to production often introduces variability\, performance limitations\, and regulatory complexity—especially when complex media components are involved. As organizations push for higher yields\, improved reproducibility\, and animal origin free workflows\, chemically defined solutions are becoming essential. \nIn this webinar\, Stanislav Pepeliaev Ph.D. will share firsthand insights from beta-testing at the Jenner Institute\, with the Gibco™ Bacto CD Supreme Fermentation Production Medium (FPM)  Plus and Bacto CD Supreme Feed (2x)\, a next-generation chemically defined formulation designed to enhance E. coli culture performance. He will discuss observed performance improvements\, robustness\, workflow integration\, and how defined systems can support consistent plasmid DNA and recombinant protein production. \nBuilding on this foundation\, fermentation expert Neelanjan (Neel) Sengupta Ph.D. will present a scale-up perspective—exploring how chemically defined media supports transition from bench-scale experiments to controlled single-use fermenter environments. The session concludes with a live Q&A featuring Stan\, Neel\, and Mark Wight to address implementation strategies and audience questions. \nBy attending\, participants will: \nUnderstand the performance advantages of chemically defined media in E. coli systems\nEvaluate real-world beta-test data supporting plasmid DNA workflows\nLearn practical scale-up considerations for transitioning to controlled fermenter systems
URL:https://thebiocalendar.com/event/defined-media-defined-results-scaling-e-coli-from-bench-to-fermenter/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/1772832182634.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260413
DTEND;VALUE=DATE:20260415
DTSTAMP:20260414T201219
CREATED:20251212T172218Z
LAST-MODIFIED:20251212T172933Z
UID:9644-1776038400-1776211199@thebiocalendar.com
SUMMARY:CMO Summit 360°
DESCRIPTION:The Largest ​​​​​​​Annual Gathering of Biotech CMOs\n  \n\n\n\n\nThe 14th annual CMO Summit 360° ® is the largest gathering of biotech Chief Medical Officers across indications\, modalities\, company stages\, professional experience levels and geographic locations. This is the conference to connect with peers and develop the skills needed to succeed as a biotech CMO. \nWe are thrilled to announce that the CMO Summit 360° is now part of Fierce Life Sciences. Combining our resources allows for greater market reach\, more networking and partnering.
URL:https://thebiocalendar.com/event/cmo-summit-360-3/
LOCATION:Boston\, MA\, 02210\, United States
CATEGORIES:Summit
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260413
DTEND;VALUE=DATE:20260417
DTSTAMP:20260414T201219
CREATED:20260109T153145Z
LAST-MODIFIED:20260109T153146Z
UID:9756-1776038400-1776383999@thebiocalendar.com
SUMMARY:Drug Discovery Chemistry
DESCRIPTION:Drug Discovery Chemistry is a dynamic conference for medicinal\, biophysical\, and computational chemists working across pharma\, biotech\, and academia. Focused on discovery and optimization challenges of small-molecule and macrocyclic drug candidates\, the 2026 event features new sessions spanning AI- and ML-driven design\, fragment- and structure-based discovery\, molecular glues and degraders\, DNA-encoded libraries\, and emerging biophysical tools. Attendees can tailor their experience by exploring concurrent tracks covering today’s most innovative approaches to drug discovery.
URL:https://thebiocalendar.com/event/drug-discovery-chemistry-2/
LOCATION:San Diego\, San Diego\, CA\, United States
CATEGORIES:Summit
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260414
DTEND;VALUE=DATE:20260416
DTSTAMP:20260414T201219
CREATED:20251125T143235Z
LAST-MODIFIED:20251125T143235Z
UID:9584-1776124800-1776297599@thebiocalendar.com
SUMMARY:American Biomanufacturing Summit
DESCRIPTION:The Generis American Biomanufacturing Summit (BIO) has a strong reputation as the leading platform for connecting senior leaders and exchanging ideas in the biopharma and biotech industries. This two-day conference is designed to bring together biopharma executives and solution providers to discuss emerging trends\, strategic insights\, and best practices in an ever-evolving biomanufacturing landscape. Join over 350 biopharma and biotech executive leaders\, including more than 50 speakers\, 150 senior-level attendees\, and hundreds of participants from solution companies at this annual event as we explore the latest challenges\, opportunities\, and innovations shaping the industry. With sessions led by top biotech executives\, the agenda will dive into critical topics such as AAV manufacturing\, cell and gene therapy\, capacity management\, quality assurance and control\, regulatory compliance\, operational excellence\, and supply chain and logistics. Network with fellow biopharma leaders and connect with leading solution providers as we uncover strategies to maximize efficiency and ensure compliance within the biomanufacturing space.
URL:https://thebiocalendar.com/event/american-biomanufacturing-summit/
LOCATION:San Francisco\, CA\, San Francisco\, CA\, United States
CATEGORIES:Summit
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260414T110000
DTEND;TZID=America/Los_Angeles:20260414T120000
DTSTAMP:20260414T201219
CREATED:20260310T161658Z
LAST-MODIFIED:20260310T161659Z
UID:10000-1776164400-1776168000@thebiocalendar.com
SUMMARY:Proactive Contamination Control in Aseptic Fill/Finish
DESCRIPTION:Join experts Herman Bozenhardt\, President of Bozenhardt Consulting\, and James Janachowski\, MS&T Site Lead\, Process Engineering for CSL Behring\, as they explore topics such as risk-based facility and equipment design\, advanced barrier technologies\, personnel and material flow optimization\, environmental monitoring trending and data analytics\, and the integration of rapid microbiological methods.
URL:https://thebiocalendar.com/event/proactive-contamination-control-in-aseptic-fill-finish/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/26_04-POL-Reg-1920x250-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260414T110000
DTEND;TZID=America/Los_Angeles:20260414T120000
DTSTAMP:20260414T201219
CREATED:20260313T114432Z
LAST-MODIFIED:20260313T114432Z
UID:10017-1776164400-1776168000@thebiocalendar.com
SUMMARY:Turbocharge CAR-T Manufacturing: Industrializing Cell Therapy with Perfusion
DESCRIPTION:As the field transitions toward scalable\, cost-efficient allogeneic CAR-T therapies\, manufacturing intensification is no longer optional\, it is essential. \nThis webinar demonstrates how perfusion using XCell® ATF technology enables rapid\, high-density CAR-T expansion in stirred-tank bioreactors while preserving critical quality attributes. Data from intensified 2 L perfusion processes show consistent production of >110 anti-CD19 CAR-T doses within a 12-day manufacturing cycle\, using serum-free media and optimized perfusion strategies. \nWe will present predictive scale-down modeling from Ambr® 250 STR to 2 L scale\, stable process control with matched volumetric power input (P/V)\, and real-time viable cell monitoring using multi-frequency capacitance. We will also cover seamless downstream integration with automated harvest systems such as Ksep®\, achieving >90% recovery. Attendees will gain practical insight into how perfusion using XCell® ATF System reduces timelines\, increases yields\, improves process control\, and establishes a scalable\, economically viable CAR-T manufacturing platform. \nKey Learning Objectives:\n~    How matched volumetric power input (P/V) enables predictive scale-down modeling and de-risked tech transfer from Ambr® 250 to 2 L scale\n~    Why XCell ATF perfusion delivers ~34% greater fold expansion than G-Rex® systems and how multi-frequency capacitance enables real-time viable cell density prediction\n~   How to integrate automated harvest systems (e.g.\, Ksep®) for >90% recovery in an industrialized allogeneic CAR-T workflow
URL:https://thebiocalendar.com/event/turbocharge-car-t-manufacturing-industrializing-cell-therapy-with-perfusion/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/04-14-26-Repligen-LinkedIn-1280x720-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260415T110000
DTEND;TZID=America/Los_Angeles:20260415T120000
DTSTAMP:20260414T201219
CREATED:20260318T143414Z
LAST-MODIFIED:20260318T143414Z
UID:10029-1776250800-1776254400@thebiocalendar.com
SUMMARY:Less Risk\, More Speed -The New Blueprint for Bioconjugate Development: A Fireside Chat
DESCRIPTION:Join this webinar to learn how an integrated CDMO+CRO model is transforming bioconjugate development by reducing risk and accelerating timelines from discovery to GMP supply. Discover actionable strategies and real-world insights to streamline your ADC and biologics programs while avoiding costly delays and late-stage failures. \nYou’ll leave with insights on:\n– How an integrated development model reduces technical & operational risk across next-gen modalities\n– Early development strategies that front-load risk identification & mitigation before it becomes costly\n– Partner and technology selection criteria — what to look for and what to avoid\n– Navigating the evolving regulatory landscape for novel bioconjugate modalities\n– Fast-track execution strategies that compress the discovery-to-GMP timeline without compromising quality
URL:https://thebiocalendar.com/event/less-risk-more-speed-the-new-blueprint-for-bioconjugate-development-a-fireside-chat/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/04-15-26-Abzena-Eblast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260415T110000
DTEND;TZID=America/Los_Angeles:20260415T120000
DTSTAMP:20260414T201219
CREATED:20260319T135546Z
LAST-MODIFIED:20260319T135546Z
UID:10041-1776250800-1776254400@thebiocalendar.com
SUMMARY:OneTeam™: Setting a New Standard for Biotech Program Visibility
DESCRIPTION:Learn how to transform your gene therapy program management by adopting the OneTeam™ approach to create a transparent\, integrated “single source of truth” that replaces fragmented reporting and improves decision-making. Explore how enhanced visibility\, standardized governance\, and a shared digital interface can strengthen sponsor-CDMO collaboration and turn outsourcing from a black box into a streamlined\, confident partnership.
URL:https://thebiocalendar.com/event/oneteam-setting-a-new-standard-for-biotech-program-visibility/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/04-15-26-Andelyn-eBlast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260416T100000
DTEND;TZID=America/Los_Angeles:20260416T120000
DTSTAMP:20260414T201219
CREATED:20260312T134959Z
LAST-MODIFIED:20260312T134959Z
UID:10013-1776333600-1776340800@thebiocalendar.com
SUMMARY:Smart Sourcing: Patient Recruitment & Retention Showcase
DESCRIPTION:A 2-hour virtual expo for clinical teams to discover and compare leading patient recruitment and engagement partners—without the time\, cost\, or travel of traditional conferences. \nChoosing the right supplier impacts enrollment timelines\, diversity goals\, and site experience. This showcase helps you evaluate multiple options in one sitting. \nWhat to expect:\n✔ Live 15-minute capability presentations from top recruitment/engagement providers\n✔ Side-by-side comparisons. See real-world capabilities.\n✔ Real-time Q&A with each presenter\n✔ Practical takeaways to accelerate enrollment\, improve diversity\, and reduce drop-off \nWhy register\nYou’ll leave with a curated shortlist of viable partners and the confidence to move faster on your next study\, saving weeks of research.
URL:https://thebiocalendar.com/event/smart-sourcing-patient-recruitment-retention-showcase-2/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/04-2026-CLSE-230x90-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260416T110000
DTEND;TZID=America/Los_Angeles:20260416T120000
DTSTAMP:20260414T201219
CREATED:20260310T162148Z
LAST-MODIFIED:20260310T162149Z
UID:10004-1776337200-1776340800@thebiocalendar.com
SUMMARY:EU&PICS Annex 1: CCS short falls after 2 years of implementation
DESCRIPTION:This advanced webinar will focus on practical learnings to improve CCS outcomes. It has become clear that three stages of CCS preparation lead to a fully compliant live document that continues through the product life cycle.  This session addresses operational challenges and regulatory expectations across sterile manufacturing\, ATMPs\, early-phase products\, and CDMO environments.  An interactive Q&A will follow the presentation\, providing the opportunity to discuss specific operational and regulatory challenges to enhance CCS programs. An interactive Q&A will follow the presentation.
URL:https://thebiocalendar.com/event/eupics-annex-1-ccs-short-falls-after-2-years-of-implementation/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/04-16-26-Korber-LinkedIn-1280x720-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260417
DTEND;VALUE=DATE:20260423
DTSTAMP:20260414T201219
CREATED:20251125T143125Z
LAST-MODIFIED:20251125T143125Z
UID:9583-1776384000-1776902399@thebiocalendar.com
SUMMARY:AACR Annual Meeting 2026
DESCRIPTION:The AACR Annual Meeting is the focal point of the cancer research community\, where scientists\, clinicians\, other health care professionals\, survivors\, patients\, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology\, translational\, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.
URL:https://thebiocalendar.com/event/aacr-annual-meeting-2026/
LOCATION:San Diego\, San Diego\, CA\, United States
CATEGORIES:Annual Meeting
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260420
DTEND;VALUE=DATE:20260422
DTSTAMP:20260414T201219
CREATED:20260316T090716Z
LAST-MODIFIED:20260316T090716Z
UID:10021-1776643200-1776815999@thebiocalendar.com
SUMMARY:ICEBB 2026: 20. International Conference on Emerging Biosensors and Biotechnology
DESCRIPTION:The International Research Conference is a federated organization dedicated to bringing together a significant number of diverse scholarly events for presentation within the conference program. Events will run over a span of time during the conference depending on the number and length of the presentations. With its high quality\, it provides an exceptional value for students\, academics and industry researchers. \nInternational Conference on Emerging Biosensors and Biotechnology aims to bring together leading academic scientists\, researchers and research scholars to exchange and share their experiences and research results on all aspects of Emerging Biosensors and Biotechnology. It also provides a premier interdisciplinary platform for researchers\, practitioners and educators to present and discuss the most recent innovations\, trends\, and concerns as well as practical challenges encountered and solutions adopted in the fields of Emerging Biosensors and Biotechnology.
URL:https://thebiocalendar.com/event/icebb-2026-20-international-conference-on-emerging-biosensors-and-biotechnology/
LOCATION:Boston\, MA\, 02210\, United States
CATEGORIES:Summit,Symposium
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260420T110000
DTEND;TZID=America/Los_Angeles:20260420T120000
DTSTAMP:20260414T201219
CREATED:20260318T142717Z
LAST-MODIFIED:20260318T142717Z
UID:10025-1776682800-1776686400@thebiocalendar.com
SUMMARY:Where Sourcing Meets Science: Performance Improvement and Cost Reduction through Innovative Collaboration
DESCRIPTION:Join this webinar to discover how variability reduction programs and animal-free peptones can optimize cell culture media for improved biotherapeutic yield\, quality\, and cost control. Learn from real-world case studies how reducing raw material variability can enhance consistency\, minimize risk\, and drive efficiency across your manufacturing process. \nKey learning objectives:\n– Demonstrating the value of peptones/yeast extracts in biotherapeutics manufacturing\n– Identifying and quantifying the cost of manufacturing variability and the benefit of process optimization in biotherapeutics\n– Demonstrating how Variability Reduction Programs successfully address raw material variability
URL:https://thebiocalendar.com/event/where-sourcing-meets-science-performance-improvement-and-cost-reduction-through-innovative-collaboration/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/04-20-26-Nu-Tek-eblast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260421
DTEND;VALUE=DATE:20260422
DTSTAMP:20260414T201219
CREATED:20251211T120046Z
LAST-MODIFIED:20251211T120127Z
UID:9643-1776729600-1776815999@thebiocalendar.com
SUMMARY:BioLabs Investor Day Philadelphia
DESCRIPTION:More than ever\, great life science startups need extensive investor connections to be successful. That’s why BioLabs joins forces with key local ecosystem partners — drawing on our international network of investor relationships — to bring the money and the talent together. \nPhiladelphia’s third annual Investor Day event will bring together life science investors from across the country with startups from Philly’s groundbreaking ecosystem for a day of pre-selected lightning pitches\, poster sessions a lively panel of expert and invite-only networking.
URL:https://thebiocalendar.com/event/biolabs-investor-day-philadelphia/
LOCATION:Philadelphia\, Philadelphia\, PA\, United States
CATEGORIES:Investor
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260421
DTEND;VALUE=DATE:20260423
DTSTAMP:20260414T201219
CREATED:20260324T074121Z
LAST-MODIFIED:20260324T074121Z
UID:10063-1776729600-1776902399@thebiocalendar.com
SUMMARY:Life Science Innovation Northwest 2026
DESCRIPTION:Life Science Innovation Northwest (LSINW) is the Pacific Northwest’s premier life science event where the entire ecosystem comes together to spark breakthroughs\, shape the future\, and accelerate what comes next. This one-and-a-half-day conference brings the region’s innovators into one room to showcase today’s most compelling discoveries and tomorrow’s biggest opportunities. \nLSINW is the can’t-miss gathering for the PNW life science community. Nowhere else will you find CEOs\, investors\, research institutions\, global health leaders\, entrepreneurs\, and public and private life science organizations connecting at this scale. With high-impact programming\, elevated networking\, and dedicated time to meet strategic partners\, collaborators\, and investors\, LSINW 2026 is designed to help attendees build meaningful relationships that move ideas and companies forward.
URL:https://thebiocalendar.com/event/life-science-innovation-northwest-2026/
LOCATION:Seattle Convention Center\, 705 Pike St.\, Seattle\, WA\, 98101\, United States
CATEGORIES:Forum,Summit
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260421T110000
DTEND;TZID=America/Los_Angeles:20260421T120000
DTSTAMP:20260414T201219
CREATED:20260325T132859Z
LAST-MODIFIED:20260325T132859Z
UID:10065-1776769200-1776772800@thebiocalendar.com
SUMMARY:Unlocking the next wave of cancer vaccines: Advancing mRNA-LNP delivery and small-scale manufacturing
DESCRIPTION:Personalized cancer vaccines (PCVs) are reshaping immuno-oncology. However\, translating these therapies into the clinic remains challenging. The progress is often slowed by critical bottlenecks – from suboptimal delivery\, limited access to novel lipid nanoparticle (LNP) formulations\, to a lack of manufacturing technologies designed for small-scale clinical production.  \nThis webinar explores how optimized ionizable LNP formulations improve the delivery of multi-epitope mRNA cancer vaccine candidates while supporting safety and immune-targeted expression. We will share findings from repeat intramuscular dosing studies demonstrating favorable tolerability and extended survival in tumor‑bearing mice.  \nYou will also learn how pairing advanced LNP design with small‑scale clinical manufacturing technologies enables a smoother transition from early development to clinical evaluation. By aligning formulation strategy with scalable process designs\, teams can ensure PCV candidates are potent and ready for clinical translation. \nJoin this webinar to learn:\n~   Why current PCV delivery strategies fall short—and how next-generation ionizable lipid formulations address safety and tissue-targeting limitations\n~   How optimized ionizable lipids enhance effective LNP-mediated delivery\, mRNA translation\, and antigen presentation for multi‑epitope mRNA cancer vaccines\n~   Key findings from repeated intramuscular dosing studies\, including maintained critical quality attributes (CQAs)\, no detectable toxicity\, and extended survival in tumor‑bearing mice\n~   Practical considerations for building PCV manufacturing workflows that transition seamlessly from concept to clinic using technologies purpose-built for small-scale clinical production \nSpeaker:\nMartin Rabel\nGlobal Sales Specialist\, BioPharma Services\, Cytiva\nMartin Rabel\, Ph.D.\, leads the commercial strategy for Cytiva’s BioPharma Services portfolio across EMEA and APAC. In this role\, he supports the advancement of nucleic acid–based therapies by enabling access to Cytiva’s proprietary lipid nanoparticle (LNP) platform and its integrated suite of nanoparticle development\, analytical\, and cGMP-compliant manufacturing services.\nMartin plays a key part in shaping and expanding this rapidly growing area of Cytiva’s offering. With a background as a trained Pharmacist and deep technical expertise in nanomedicine and RNA–LNP technologies\, he is committed to delivering exceptional customer guidance along with strong scientific and commercial excellence.
URL:https://thebiocalendar.com/event/unlocking-the-next-wave-of-cancer-vaccines-advancing-mrna-lnp-delivery-and-small-scale-manufacturing/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/04-21-26-Cytiva-Reg-1920x250-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260421T110000
DTEND;TZID=America/Los_Angeles:20260421T120000
DTSTAMP:20260414T201219
CREATED:20260327T122913Z
LAST-MODIFIED:20260327T122913Z
UID:10096-1776769200-1776772800@thebiocalendar.com
SUMMARY:We Mapped What Sites Actually Do to Prepare Source Docs - The Results Are Eye-Opening
DESCRIPTION:In late 2025\, Tufts CSDD and CRIO conducted a survey among a global community of investigative sites to better understand how sites translate clinical trial protocols and related information into practical tools such as template source documents\, study plans\, calendars\, worksheets and shadow charts for the purposes of ensuring compliant\, efficient\, and high-quality data collection. In total\, 209 sites from a variety of settings responded. This session will review key takeaways from this research and discuss their implications.  \nThis source preparation process is not well understood and the lack of standardized terms describing the process are a source of confusion.  At the same time\, it is widely acknowledged that the process of source document preparation at investigative sites is inefficient and highly fragmented. This webinar will provide an overview to the comprehensive mapping of systems and workflows that investigative sites use to capture\, manage and transmit clinical research data; characterize pain points and challenges that drive delays; and identify opportunities to improve efficiency\, speed and quality. \nThe webinar will begin with a short presentation of the study results. Next\, a panel of investigative site representatives will discuss the findings and insights. \nKey learning objectives: \nReview the typical site workflow for preparing source documents and the critical and rate-limiting documents needed\n– Examine the roles and work effort required to prepare source documents and how this varies based on protocol complexity\n– Discuss the wide range of paper and electronic systems that sites use to capture relevant study information\n– Identify opportunities for sponsors\, sites and service providers to enhance the protocol-guided source preparation process and accelerate study activation times
URL:https://thebiocalendar.com/event/we-mapped-what-sites-actually-do-to-prepare-source-docs-the-results-are-eye-opening/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/04-21-26-CRIO-eBlast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260421T130000
DTEND;TZID=America/Los_Angeles:20260421T140000
DTSTAMP:20260414T201219
CREATED:20260318T144018Z
LAST-MODIFIED:20260318T144018Z
UID:10033-1776776400-1776780000@thebiocalendar.com
SUMMARY:Small Molecule Drug Product Capabilities Update
DESCRIPTION:Watch leading CDMOs share their current capabilities\, facility locations\, and timelines – to help you identify options for your development and manufacturing needs. \nWhat can you expect? – Short\, digital presentations to give you an inside look at the available capacity of industry suppliers. You will have the opportunity to ask questions of each CDMO to better understand if they can meet your needs – all from the convenience of your computer! \nPlease note that this event is for biopharma companies seeking to connect with CDMOs who have the capabilities that fit their needs.
URL:https://thebiocalendar.com/event/small-molecule-drug-product-capabilities-update/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/Biocal-11.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260422
DTEND;VALUE=DATE:20260424
DTSTAMP:20260414T201219
CREATED:20260116T133300Z
LAST-MODIFIED:20260116T133300Z
UID:9795-1776816000-1776988799@thebiocalendar.com
SUMMARY:AI x Next Generation Clinical Trials
DESCRIPTION:AI x Next Generation Clinical Trials is the premier event for exploring how artificial intelligence is revolutionizing clinical trial design\, execution\, and outcomes. This inaugural conference brings together industry leaders\, AI innovators\, and clinical trial experts to discuss the latest advancements in AI-driven patient recruitment\, trial optimization\, and data analysis. Gain actionable insights into leveraging AI to accelerate timelines\, reduce costs\, and improve trial success rates. With a focus on real-world applications\, emerging technologies\, and regulatory considerations\, this event is your opportunity to transform your approach to innovation and efficiency.
URL:https://thebiocalendar.com/event/ai-x-next-generation-clinical-trials/
LOCATION:Boston\, MA\, 02210\, United States
CATEGORIES:Summit
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260422T110000
DTEND;TZID=America/Los_Angeles:20260422T120000
DTSTAMP:20260414T201219
CREATED:20260318T144305Z
LAST-MODIFIED:20260318T144305Z
UID:10037-1776855600-1776859200@thebiocalendar.com
SUMMARY:Fill Finish Capabilities Update
DESCRIPTION:Explore leading CDMOs’ capabilities\, facility locations\, and timelines to identify the right partners for your development and manufacturing needs. Gain insights into critical fill-finish processes\, including sterile filling\, lyophilization\, and packaging\, while engaging directly with suppliers through interactive presentations. \nPlease note that this event is for biopharma companies seeking available capacity to connect with CDMOs who have that capacity available.
URL:https://thebiocalendar.com/event/fill-finish-capabilities-update/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/Biocal-12.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260422T110000
DTEND;TZID=America/Los_Angeles:20260422T120000
DTSTAMP:20260414T201219
CREATED:20260326T133852Z
LAST-MODIFIED:20260326T133852Z
UID:10074-1776855600-1776859200@thebiocalendar.com
SUMMARY:One Program\, Many CDMOs: Managing Multi-Partner Strategies
DESCRIPTION:Join Outsourced Pharma Live’s next virtual event to learn practical strategies for aligning external partners\, improving oversight\, and managing the real cost and risk of outsourcing across multiple locations.
URL:https://thebiocalendar.com/event/one-program-many-cdmos-managing-multi-partner-strategies/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/26_04-OPL-HTML-600x300-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260423
DTEND;VALUE=DATE:20260424
DTSTAMP:20260414T201219
CREATED:20260410T131837Z
LAST-MODIFIED:20260410T131837Z
UID:10189-1776902400-1776988799@thebiocalendar.com
SUMMARY:Biocom Converge Summit
DESCRIPTION:Biocom’s Converge Summit brings together the brightest minds in the life science\, medtech and technology sectors to explore transformative ideas\, build relationships and ignite partnerships that can change the world. Attendees will have the chance to engage in critical conversations with industry leaders\, explore the latest research and development\, and gain valuable insights into the emerging trends and opportunities that are driving growth and innovation.
URL:https://thebiocalendar.com/event/biocom-converge-summit/
LOCATION:South San Francisco\, CA\, CA\, 94080\, United States
CATEGORIES:Summit
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260423T010000
DTEND;TZID=America/Los_Angeles:20260423T140000
DTSTAMP:20260414T201219
CREATED:20260320T124345Z
LAST-MODIFIED:20260320T124345Z
UID:10049-1776906000-1776952800@thebiocalendar.com
SUMMARY:Advancing in-line PAT Solutions for Real-Time Batch Analysis
DESCRIPTION:This webinar explores how in-line PAT and real-time metabolic monitoring improve batch control\, reduce risk\, and increase yield. Learn how continuous glucose and lactate sensing provides accurate\, non-invasive data to optimize processes\, enhance consistency\, and support faster\, more informed decision-making.
URL:https://thebiocalendar.com/event/advancing-in-line-pat-solutions-for-real-time-batch-analysis/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/04-23-26-PHC-eBlast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260423T110000
DTEND;TZID=America/Los_Angeles:20260423T120000
DTSTAMP:20260414T201219
CREATED:20260320T124032Z
LAST-MODIFIED:20260320T124032Z
UID:10045-1776942000-1776945600@thebiocalendar.com
SUMMARY:Unlocking The Power Of Primary Care In Chronic Disease Research
DESCRIPTION:Chronic disease management largely takes place in primary care settings\, where patients rely on trusted physicians within their communities. A historically underrepresented and untapped area of clinical research\, engaging primary care physicians (PCPs) presents a powerful opportunity to access new\, more diverse patient pools that are critical to success in a competitive research environment. \nJoin our experts as they explore the opportunities presented by utilizing PCPs in chronic disease research – including accelerating patient identification\, accessing underrepresented patient populations\, retaining patients in long-term trials and better understanding how potential treatments work in a real-world setting. \nKey learning objectives:\n– Understanding the critical role PCPs play in chronic disease management and the value they bring to clinical research\n– Identifying best practices for training and supporting PCPs as investigators and referral partners\n– Navigating global regulations and guidance related to engaging PCPs across regions
URL:https://thebiocalendar.com/event/unlocking-the-power-of-primary-care-in-chronic-disease-research/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/Untitled-design-60.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260423T110000
DTEND;TZID=America/Los_Angeles:20260423T120000
DTSTAMP:20260414T201219
CREATED:20260331T195345Z
LAST-MODIFIED:20260331T195345Z
UID:10121-1776942000-1776945600@thebiocalendar.com
SUMMARY:Just Breathe: Increasing Efficacy And Expanding Targets With Inhalation Delivery
DESCRIPTION:This Drug Delivery panel discussion will illuminate ways in which innovations in inhalation\, via both oral and nasal routes to respiratory pathways and the lungs\, are increasing patient convenience and therapeutic efficacy while expanding the range of targeted indications. Host Tom von Gunden will engage expert panelists Nani Kadrichu\, David Morton\, Stephen Stein\, and Geraldine Venthoye in a focused look at advances in formulation science and device technology for inhalers\, nebulizers\, and combination products. \nThe panel will illuminate formulation and device design considerations for various scenarios\, including:\no    Overcoming delivery challenges while addressing common or unmet therapeutic needs\no    Leveraging the lungs as a pathway to therapeutic indications beyond respiratory\no    Fostering non-clinical applications\, including for at home\, self-administration\no    Maintaining affordability while advancing sustainable\, “green” initiatives\no    Transitioning formerly IV- or injection-only administered therapies (e.g.\, large molecule biologics) to inhalation options)
URL:https://thebiocalendar.com/event/just-breathe-increasing-efficacy-and-expanding-targets-with-inhalation-delivery/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/Biocal-13.png
END:VEVENT
END:VCALENDAR